ID   TAP1_HUMAN              Reviewed;         748 AA.
AC   Q03518; Q16149; Q96CP4;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-FEB-2022, sequence version 3.
DT   28-JUN-2023, entry version 229.
DE   RecName: Full=Antigen peptide transporter 1;
DE            Short=APT1;
DE            EC=7.4.2.14 {ECO:0000269|PubMed:11274390, ECO:0000269|PubMed:25377891, ECO:0000269|PubMed:25656091};
DE   AltName: Full=ATP-binding cassette sub-family B member 2;
DE   AltName: Full=Peptide supply factor 1 {ECO:0000303|PubMed:1946428};
DE   AltName: Full=Peptide transporter PSF1;
DE            Short=PSF-1 {ECO:0000303|PubMed:1946428};
DE   AltName: Full=Peptide transporter TAP1;
DE   AltName: Full=Peptide transporter involved in antigen processing 1;
DE   AltName: Full=Really interesting new gene 4 protein;
DE            Short=RING4 {ECO:0000303|PubMed:1538751};
GN   Name=TAP1 {ECO:0000303|PubMed:10605026, ECO:0000312|HGNC:HGNC:43};
GN   Synonyms=ABCB2, PSF1, RING4, Y3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2259383; DOI=10.1038/348741a0;
RA   Trowsdale J., Hanson I., Mockridge I., Beck S., Townsend A., Kelly A.;
RT   "Sequences encoded in the class II region of the MHC related to the 'ABC'
RT   superfamily of transporters.";
RL   Nature 348:741-744(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1453454; DOI=10.1016/0022-2836(92)90832-5;
RA   Beck S., Kelly A., Radley E., Khurshid F., Alderton R.P., Trowsdale J.;
RT   "DNA sequence analysis of 66 kb of the human MHC class II region encoding a
RT   cluster of genes for antigen processing.";
RL   J. Mol. Biol. 228:433-441(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8568858; DOI=10.1006/jmbi.1996.0001;
RA   Beck S., Abdulla S., Alderton R.P., Glynne R.J., Gut I.G., Hosking L.K.,
RA   Jackson A., Kelly A., Newell W.R., Sanseau P., Radley E., Thorpe K.L.,
RA   Trowsdale J.;
RT   "Evolutionary dynamics of non-coding sequences within the class II region
RT   of the human MHC.";
RL   J. Mol. Biol. 255:1-13(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS VAL-333; LEU-458; GLY-637 AND GLN-648,
RP   AND POLYMORPHISM.
RC   TISSUE=Blood;
RX   PubMed=8248212; DOI=10.1073/pnas.90.23.11079;
RA   Jackson D.G., Capra J.D.;
RT   "TAP1 alleles in insulin-dependent diabetes mellitus: a newly defined
RT   centromeric boundary of disease susceptibility.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:11079-11083(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 123-552.
RX   PubMed=2259384; DOI=10.1038/348744a0;
RA   Spies T., Bresnahan M., Bahram S., Arnold D., Blanck G., Mellins E.,
RA   Pious D., Demars R.;
RT   "A gene in the human major histocompatibility complex class II region
RT   controlling the class I antigen presentation pathway.";
RL   Nature 348:744-747(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 631-663, VARIANTS GLY-637 AND GLN-648, AND
RP   POLYMORPHISM.
RX   PubMed=8168860; DOI=10.1007/bf00189240;
RA   Szafer F., Oksenberg J.R., Steinman L.;
RT   "New allelic polymorphisms in TAP genes.";
RL   Immunogenetics 39:374-374(1994).
RN   [10]
RP   INDUCTION BY IFNG.
RX   PubMed=1946428; DOI=10.1073/pnas.88.22.10094;
RA   Bahram S., Arnold D., Bresnahan M., Strominger J.L., Spies T.;
RT   "Two putative subunits of a peptide pump encoded in the human major
RT   histocompatibility complex class II region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10094-10098(1991).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=1589036; DOI=10.1038/357342a0;
RA   Kleijmeer M.J., Kelly A., Geuze H.J., Slot J.W., Townsend A., Trowsdale J.;
RT   "Location of MHC-encoded transporters in the endoplasmic reticulum and cis-
RT   Golgi.";
RL   Nature 357:342-344(1992).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH TAP2.
RX   PubMed=1538751; DOI=10.1038/355641a0;
RA   Kelly A., Powis S.H., Kerr L.A., Mockridge I., Elliott T., Bastin J.,
RA   Uchanska-Ziegler B., Ziegler A., Trowsdale J., Townsend A.;
RT   "Assembly and function of the two ABC transporter proteins encoded in the
RT   human major histocompatibility complex.";
RL   Nature 355:641-644(1992).
RN   [13]
RP   FUNCTION.
RX   PubMed=7500034; DOI=10.1084/jem.182.6.1883;
RA   van Endert P.M., Riganelli D., Greco G., Fleischhauer K., Sidney J.,
RA   Sette A., Bach J.F.;
RT   "The peptide-binding motif for the human transporter associated with
RT   antigen processing.";
RL   J. Exp. Med. 182:1883-1895(1995).
RN   [14]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS US12/ICP47 (MICROBIAL INFECTION).
RX   PubMed=7760936; DOI=10.1038/375415a0;
RA   Frueh K., Ahn K., Djaballah H., Sempe P., van Endert P.M., Tampe R.,
RA   Peterson P.A., Yang Y.;
RT   "A viral inhibitor of peptide transporters for antigen presentation.";
RL   Nature 375:415-418(1995).
RN   [15]
RP   INTERACTION WITH HLA-A*02-B2M.
RX   PubMed=8805302; DOI=10.1016/s0960-9822(02)00611-5;
RA   Lewis J.W., Neisig A., Neefjes J., Elliott T.;
RT   "Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally
RT   relevant interaction with TAP.";
RL   Curr. Biol. 6:873-883(1996).
RN   [16]
RP   ACTIVITY REGULATION (MICROBIAL INFECTION), AND INHIBITION BY US12/ICP47.
RX   PubMed=8670825; DOI=10.1002/j.1460-2075.1996.tb00689.x;
RA   Ahn K., Meyer T.H., Uebel S., Sempe P., Djaballah H., Yang Y.,
RA   Peterson P.A., Frueh K., Tampe R.;
RT   "Molecular mechanism and species specificity of TAP inhibition by herpes
RT   simplex virus ICP47.";
RL   EMBO J. 15:3247-3255(1996).
RN   [17]
RP   INTERACTION WITH HLA-A*02-B2M.
RX   PubMed=8630735; DOI=10.1016/s1074-7613(00)80416-1;
RA   Peace-Brewer A.L., Tussey L.G., Matsui M., Li G., Quinn D.G.,
RA   Frelinger J.A.;
RT   "A point mutation in HLA-A*0201 results in failure to bind the TAP complex
RT   and to present virus-derived peptides to CTL.";
RL   Immunity 4:505-514(1996).
RN   [18]
RP   PEPTIDE-BINDING SITE.
RX   PubMed=8955196;
RA   Nijenhuis M., Hammerling G.J.;
RT   "Multiple regions of the transporter associated with antigen processing
RT   (TAP) contribute to its peptide binding site.";
RL   J. Immunol. 157:5467-5477(1996).
RN   [19]
RP   TISSUE SPECIFICITY, INDUCTION, AND INDUCTION (MICROBIAL INFECTION).
RX   PubMed=9310490;
RA   Zeidler R., Eissner G., Meissner P., Uebel S., Tampe R., Lazis S.,
RA   Hammerschmidt W.;
RT   "Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr
RT   virus-encoded interleukin-10.";
RL   Blood 90:2390-2397(1997).
RN   [20]
RP   ACTIVITY REGULATION (MICROBIAL INFECTION), AND INHIBITION BY US6
RP   GLYCOPROTEIN.
RX   PubMed=9175839; DOI=10.1016/s1074-7613(00)80349-0;
RA   Ahn K., Gruhler A., Galocha B., Jones T.R., Wiertz E.J.H.J., Ploegh H.L.,
RA   Peterson P.A., Yang Y., Frueh K.;
RT   "The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide
RT   translocation by TAP.";
RL   Immunity 6:613-621(1997).
RN   [21]
RP   FUNCTION.
RX   PubMed=9256420; DOI=10.1073/pnas.94.17.8976;
RA   Uebel S., Kraas W., Kienle S., Wiesmueller K.H., Jung G., Tampe R.;
RT   "Recognition principle of the TAP transporter disclosed by combinatorial
RT   peptide libraries.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:8976-8981(1997).
RN   [22]
RP   SUBUNIT, AND INTERACTION WITH HLA-E-B2M.
RX   PubMed=9427624; DOI=10.1016/s0960-9822(98)70014-4;
RA   Braud V.M., Allan D.S., Wilson D., McMichael A.J.;
RT   "TAP- and tapasin-dependent HLA-E surface expression correlates with the
RT   binding of an MHC class I leader peptide.";
RL   Curr. Biol. 8:1-10(1998).
RN   [23]
RP   INTERACTION WITH ADENOVIRUS E3-19K GLYCOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=10227971;
RA   Bennett E.M., Bennink J.R., Yewdell J.W., Brodsky F.M.;
RT   "Adenovirus E19 has two mechanisms for affecting class I MHC expression.";
RL   J. Immunol. 162:5049-5052(1999).
RN   [24]
RP   SUBUNIT, AND INTERACTION WITH HLA-F.
RX   PubMed=10605026; DOI=10.4049/jimmunol.164.1.319;
RA   Wainwright S.D., Biro P.A., Holmes C.H.;
RT   "HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib
RT   protein with a restricted expression pattern.";
RL   J. Immunol. 164:319-328(2000).
RN   [25]
RP   ACTIVITY REGULATION (MICROBIAL INFECTION), AND INHIBITION BY US6
RP   GLYCOPROTEIN.
RX   PubMed=11157746; DOI=10.1093/emboj/20.3.387;
RA   Hewitt E.W., Gupta S.S., Lehner P.J.;
RT   "The human cytomegalovirus gene product US6 inhibits ATP binding by TAP.";
RL   EMBO J. 20:387-396(2001).
RN   [26]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11274390; DOI=10.1073/pnas.061467898;
RA   Gorbulev S., Abele R., Tampe R.;
RT   "Allosteric crosstalk between peptide-binding, transport, and ATP
RT   hydrolysis of the ABC transporter TAP.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:3732-3737(2001).
RN   [27]
RP   INTERACTION WITH PSMB5 AND PSMB8.
RX   PubMed=15488952; DOI=10.1016/j.molimm.2004.07.005;
RA   Begley G.S., Horvath A.R., Taylor J.C., Higgins C.F.;
RT   "Cytoplasmic domains of the transporter associated with antigen processing
RT   and P-glycoprotein interact with subunits of the proteasome.";
RL   Mol. Immunol. 42:137-141(2005).
RN   [28]
RP   INTERACTION WITH EPSTEIN-VIRUS/EBV PROTEIN BNLF2A (MICROBIAL INFECTION).
RX   PubMed=19201886; DOI=10.4049/jimmunol.0803218;
RA   Horst D., van Leeuwen D., Croft N.P., Garstka M.A., Hislop A.D.,
RA   Kremmer E., Rickinson A.B., Wiertz E.J.H.J., Ressing M.E.;
RT   "Specific targeting of the EBV lytic phase protein BNLF2a to the
RT   transporter associated with antigen processing results in impairment of HLA
RT   class I-restricted antigen presentation.";
RL   J. Immunol. 182:2313-2324(2009).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TAPBP.
RX   PubMed=22638925; DOI=10.1007/s00018-012-1005-6;
RA   Hulpke S., Tomioka M., Kremmer E., Ueda K., Abele R., Tampe R.;
RT   "Direct evidence that the N-terminal extensions of the TAP complex act as
RT   autonomous interaction scaffolds for the assembly of the MHC I peptide-
RT   loading complex.";
RL   Cell. Mol. Life Sci. 69:3317-3327(2012).
RN   [31]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR,
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-674.
RX   PubMed=25377891; DOI=10.1038/ncomms6419;
RA   Grossmann N., Vakkasoglu A.S., Hulpke S., Abele R., Gaudet R., Tampe R.;
RT   "Mechanistic determinants of the directionality and energetics of active
RT   export by a heterodimeric ABC transporter.";
RL   Nat. Commun. 5:5419-5419(2014).
RN   [32]
RP   FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND ACTIVITY REGULATION
RP   (MICROBIAL INFECTION).
RX   PubMed=25656091; DOI=10.1038/ncomms7199;
RA   Fischbach H., Doering M., Nikles D., Lehnert E., Baldauf C., Kalinke U.,
RA   Tampe R.;
RT   "Ultrasensitive quantification of TAP-dependent antigen
RT   compartmentalization in scarce primary immune cell subsets.";
RL   Nat. Commun. 6:6199-6199(2015).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [34]
RP   FUNCTION, SUBUNIT, INTERACTION WITH TAPBP, SITE, AND MUTAGENESIS OF ASP-32.
RX   PubMed=26611325; DOI=10.1038/srep17341;
RA   Blees A., Reichel K., Trowitzsch S., Fisette O., Bock C., Abele R.,
RA   Hummer G., Schaefer L.V., Tampe R.;
RT   "Assembly of the MHC I peptide-loading complex determined by a conserved
RT   ionic lock-switch.";
RL   Sci. Rep. 5:17341-17341(2015).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 489-748 IN COMPLEX WITH ADP AND
RP   MAGNESIUM, AND COFACTOR.
RX   PubMed=11532960; DOI=10.1093/emboj/20.17.4964;
RA   Gaudet R., Wiley D.C.;
RT   "Structure of the ABC ATPase domain of human TAP1, the transporter
RT   associated with antigen processing.";
RL   EMBO J. 20:4964-4972(2001).
RN   [36]
RP   VARIANTS VAL-333 AND GLY-637, AND POLYMORPHISM.
RX   PubMed=1570316; DOI=10.1073/pnas.89.9.3932;
RA   Colonna M., Bresnahan M., Bahram S., Strominger J.L., Spies T.;
RT   "Allelic variants of the human putative peptide transporter involved in
RT   antigen processing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3932-3936(1992).
RN   [37]
RP   VARIANT GLN-659.
RX   PubMed=8640228; DOI=10.1038/ng0696-210;
RA   Chen H.L., Gabrilovich D., Tampe R., Girgis K.R., Nadaf S., Carbone D.P.;
RT   "A functionally defective allele of TAP1 results in loss of MHC class I
RT   antigen presentation in a human lung cancer.";
RL   Nat. Genet. 13:210-213(1996).
RN   [38]
RP   INVOLVEMENT IN BLS1.
RX   PubMed=10074494; DOI=10.1172/jci5335;
RA   Furukawa H., Murata S., Yabe T., Shimbara N., Keicho N., Kashiwase K.,
RA   Watanabe K., Ishikawa Y., Akaza T., Tadokoro K., Tohma S., Inoue T.,
RA   Tokunaga K., Yamamoto K., Tanaka K., Juji T.;
RT   "Splice acceptor site mutation of the transporter associated with antigen
RT   processing-1 gene in human bare lymphocyte syndrome.";
RL   J. Clin. Invest. 103:755-758(1999).
RN   [39]
RP   VARIANTS VAL-333; VAL-370; LEU-458; ILE-518; GLY-637 AND GLN-648, AND
RP   POLYMORPHISM.
RX   PubMed=11250043; DOI=10.1016/s0198-8859(00)00259-7;
RA   Tang J., Freedman D.O., Allen S., Karita E., Musonda R., Braga C.,
RA   Margolick J., Kaslow R.A.;
RT   "TAP1 polymorphisms in several human ethnic groups: characteristics,
RT   evolution, and genotyping strategies.";
RL   Hum. Immunol. 62:256-268(2001).
RN   [40]
RP   VARIANTS SER-7; ARG-17; VAL-333; VAL-370; CYS-419; LEU-458; GLY-637 AND
RP   GLN-648, AND POLYMORPHISM.
RX   PubMed=12878362; DOI=10.1016/s0198-8859(03)00110-1;
RA   Lajoie J., Zijenah L.S., Faucher M.C., Ward B.J., Roger M.;
RT   "Novel TAP1 polymorphisms in indigenous Zimbabweans: their potential
RT   implications on TAP function and in human diseases.";
RL   Hum. Immunol. 64:823-829(2003).
CC   -!- FUNCTION: ABC transporter associated with antigen processing. In
CC       complex with TAP2 mediates unidirectional translocation of peptide
CC       antigens from cytosol to endoplasmic reticulum (ER) for loading onto
CC       MHC class I (MHCI) molecules (PubMed:25656091, PubMed:25377891). Uses
CC       the chemical energy of ATP to export peptides against the concentration
CC       gradient (PubMed:25377891). During the transport cycle alternates
CC       between 'inward-facing' state with peptide binding site facing the
CC       cytosol to 'outward-facing' state with peptide binding site facing the
CC       ER lumen. Peptide antigen binding to ATP-loaded TAP1-TAP2 induces a
CC       switch to hydrolysis-competent 'outward-facing' conformation ready for
CC       peptide loading onto nascent MHCI molecules. Subsequently ATP
CC       hydrolysis resets the transporter to the 'inward facing' state for a
CC       new cycle (PubMed:25377891, PubMed:25656091, PubMed:11274390).
CC       Typically transports intracellular peptide antigens of 8 to 13 amino
CC       acids that arise from cytosolic proteolysis via IFNG-induced
CC       immunoproteasome. Binds peptides with free N- and C-termini, the first
CC       three and the C-terminal residues being critical. Preferentially
CC       selects peptides having a highly hydrophobic residue at position 3 and
CC       hydrophobic or charged residues at the C-terminal anchor. Proline at
CC       position 2 has the most destabilizing effect (PubMed:7500034,
CC       PubMed:9256420, PubMed:11274390). As a component of the peptide loading
CC       complex (PLC), acts as a molecular scaffold essential for peptide-MHCI
CC       assembly and antigen presentation (PubMed:26611325, PubMed:1538751,
CC       PubMed:25377891). {ECO:0000269|PubMed:11274390,
CC       ECO:0000269|PubMed:1538751, ECO:0000269|PubMed:25377891,
CC       ECO:0000269|PubMed:25656091, ECO:0000269|PubMed:26611325,
CC       ECO:0000269|PubMed:7500034, ECO:0000269|PubMed:9256420}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a peptide antigen(in) + ATP + H2O = a peptide antigen(out) +
CC         ADP + H(+) + phosphate; Xref=Rhea:RHEA:65972, Rhea:RHEA-COMP:16941,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:166823, ChEBI:CHEBI:456216;
CC         EC=7.4.2.14; Evidence={ECO:0000269|PubMed:11274390,
CC         ECO:0000269|PubMed:25377891, ECO:0000269|PubMed:25656091};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:65973;
CC         Evidence={ECO:0000305|PubMed:11274390, ECO:0000305|PubMed:25377891,
CC         ECO:0000305|PubMed:25656091};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11532960, ECO:0000269|PubMed:25377891,
CC         ECO:0007744|PDB:1JJ7};
CC   -!- ACTIVITY REGULATION: Inhibited at high ER lumenal peptide
CC       concentrations. {ECO:0000269|PubMed:25377891}.
CC   -!- ACTIVITY REGULATION: (Microbial infection) Inhibited by herpes simplex
CC       virus US12/ICP47 protein, which blocks the peptide-binding site of
CC       TAP1-TAP2. {ECO:0000269|PubMed:25656091, ECO:0000269|PubMed:8670825}.
CC   -!- ACTIVITY REGULATION: (Microbial infection) Inhibited by human
CC       cytomegalovirus US6 glycoprotein, which binds to the lumenal side of
CC       TAP1-TAP2 complex and inhibits peptide translocation by specifically
CC       blocking ATP-binding and preventing TAP1-TAP2 conformational
CC       rearrangement induced by peptide binding. {ECO:0000269|PubMed:11157746,
CC       ECO:0000269|PubMed:25656091, ECO:0000269|PubMed:9175839}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.3 mM for ATP {ECO:0000269|PubMed:11274390};
CC         KM=0.099 mM for ATP {ECO:0000269|PubMed:25377891};
CC         Vmax=2 umol/min/mg enzyme toward ATP {ECO:0000269|PubMed:11274390};
CC   -!- SUBUNIT: Heterodimer of TAP1 and TAP2 (TAP1-TAP2) (PubMed:1538751). A
CC       component of the peptide loading complex (PLC), interacts via TAPBP
CC       with MHCI heterodimer; this interaction mediates peptide-MHCI assembly
CC       (PubMed:26611325). Recruits TAPBP in a 1:1 stoichiometry
CC       (PubMed:22638925). Interacts with classical MHCI such as HLA-A*02-B2M;
CC       this interaction is obligatory for the loading of peptide epitopes
CC       (PubMed:8805302, PubMed:8630735). Interacts with non-classical MHCI
CC       molecules including HLA-E-B2M and HLA-F-B2M as well as PLC component
CC       CALR before the peptide loading (PubMed:9427624, PubMed:10605026).
CC       Interacts with PSMB5 and PSMB8 (PubMed:15488952).
CC       {ECO:0000269|PubMed:10605026, ECO:0000269|PubMed:1538751,
CC       ECO:0000269|PubMed:15488952, ECO:0000269|PubMed:22638925,
CC       ECO:0000269|PubMed:26611325, ECO:0000269|PubMed:8630735,
CC       ECO:0000269|PubMed:8805302, ECO:0000269|PubMed:9427624}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus
CC       BNLF2a. {ECO:0000269|PubMed:19201886}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus
CC       US12/ICP47. {ECO:0000269|PubMed:7760936}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with adenovirus E3-19K
CC       glycoprotein, which binds TAP1-TAP2 and acts as a TAPBP inhibitor,
CC       preventing TAP1-TAP2 association with MHCI.
CC       {ECO:0000269|PubMed:10227971}.
CC   -!- INTERACTION:
CC       Q03518; Q13520: AQP6; NbExp=3; IntAct=EBI-747259, EBI-13059134;
CC       Q03518; P27797: CALR; NbExp=2; IntAct=EBI-747259, EBI-1049597;
CC       Q03518; Q9Y282: ERGIC3; NbExp=3; IntAct=EBI-747259, EBI-781551;
CC       Q03518; P60508: ERVFRD-1; NbExp=3; IntAct=EBI-747259, EBI-17973325;
CC       Q03518; P57678: GEMIN4; NbExp=3; IntAct=EBI-747259, EBI-356700;
CC       Q03518; Q8TDT2: GPR152; NbExp=3; IntAct=EBI-747259, EBI-13345167;
CC       Q03518; Q5TA81: LCE2C; NbExp=3; IntAct=EBI-747259, EBI-11973993;
CC       Q03518; P07237: P4HB; NbExp=4; IntAct=EBI-747259, EBI-395883;
CC       Q03518; P30101: PDIA3; NbExp=5; IntAct=EBI-747259, EBI-979862;
CC       Q03518; Q6ZMZ0: RNF19B; NbExp=3; IntAct=EBI-747259, EBI-2466594;
CC       Q03518; Q14973: SLC10A1; NbExp=3; IntAct=EBI-747259, EBI-3923031;
CC       Q03518; Q3KNW5: SLC10A6; NbExp=3; IntAct=EBI-747259, EBI-18159983;
CC       Q03518; Q9NQQ7-3: SLC35C2; NbExp=3; IntAct=EBI-747259, EBI-17295964;
CC       Q03518; Q8WWF3: SSMEM1; NbExp=3; IntAct=EBI-747259, EBI-17280858;
CC       Q03518; Q03519: TAP2; NbExp=14; IntAct=EBI-747259, EBI-780781;
CC       Q03518; O15533: TAPBP; NbExp=13; IntAct=EBI-747259, EBI-874801;
CC       Q03518; Q13769: THOC5; NbExp=4; IntAct=EBI-747259, EBI-5280316;
CC       Q03518; Q9NUH8: TMEM14B; NbExp=3; IntAct=EBI-747259, EBI-8638294;
CC       Q03518; P0C739: BNLF2a; Xeno; NbExp=9; IntAct=EBI-747259, EBI-9346744;
CC       Q03518; Q77CE4: gN; Xeno; NbExp=6; IntAct=EBI-747259, EBI-11303846;
CC       Q03518-2; Q03519: TAP2; NbExp=4; IntAct=EBI-31441209, EBI-780781;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:1589036, ECO:0000269|PubMed:22638925}; Multi-pass
CC       membrane protein {ECO:0000255}. Note=The transmembrane segments seem to
CC       form a pore in the membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q03518-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q03518-2; Sequence=VSP_061432;
CC   -!- TISSUE SPECIFICITY: Higly expressed in professional APCs monocytes and
CC       dendritic cells as well as in lymphocyte subsets T cells, B cells and
CC       NK cells. {ECO:0000269|PubMed:25656091, ECO:0000269|PubMed:9310490}.
CC   -!- INDUCTION: Up-regulated by IFNG (PubMed:1946428). Down-regulated by
CC       IL10 (PubMed:9310490). {ECO:0000269|PubMed:1946428,
CC       ECO:0000269|PubMed:9310490}.
CC   -!- INDUCTION: (Microbial infection) Down-regulated by BCRF1/viral IL10.
CC       {ECO:0000269|PubMed:9310490}.
CC   -!- DOMAIN: The peptide-binding site is shared between the cytoplasmic
CC       loops of TAP1 and TAP2. {ECO:0000269|PubMed:8955196}.
CC   -!- DOMAIN: The nucleotide-binding domain (NBD) mediates ATP hydrolysis
CC       coupled to peptide translocation. Two ATP molecules are accommodated at
CC       distinct nucleotide binding sites (NBS) at TAP1-TAP2 dimer interface.
CC       Each NBS is formed by Walker A (GxxGxGKST) and Q-loop motifs from NBD
CC       of one subunit, while the NBD from the second subunit completes the
CC       active site by contributing the C loop motif (LSGGQ). Each ATP molecule
CC       is coordinated via the beta- and gamma-phosphates to a Mg2+ ion, which
CC       is necessary for ATP hydrolysis. {ECO:0000250|UniProtKB:P36370}.
CC   -!- POLYMORPHISM: There are five common alleles; TAP1*01:01 (PSF1A),
CC       TAP1*02:01 (PSF1B), TAP1*03:01 (PSF1C), TAP1*01:04 and TAP1*x. The
CC       sequence of TAP1*01:01 is shown here. {ECO:0000269|PubMed:11250043,
CC       ECO:0000269|PubMed:12878362, ECO:0000269|PubMed:1570316,
CC       ECO:0000269|PubMed:8168860, ECO:0000269|PubMed:8248212}.
CC   -!- DISEASE: Bare lymphocyte syndrome 1 (BLS1) [MIM:604571]: A HLA class I
CC       deficiency. Contrary to bare lymphocyte syndromes type 2 and type 3,
CC       which are characterized by early-onset severe combined
CC       immunodeficiency, class I antigen deficiencies are not accompanied by
CC       particular pathologic manifestations during the first years of life.
CC       Systemic infections have not been described. Chronic bacterial
CC       infections, often beginning in the first decade of life, are restricted
CC       to the respiratory tract. {ECO:0000269|PubMed:10074494}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB family.
CC       MHC peptide exporter (TC 3.A.1.209) subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA47025.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAA60785.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=TAP1base; Note=TAP1 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/TAP1base/";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC proteins;
CC       URL="http://abcm2.hegelab.org/search";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X57522; CAA40741.1; -; mRNA.
DR   EMBL; X66401; CAA47025.1; ALT_INIT; Genomic_DNA.
DR   EMBL; X87344; CAA60785.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AL669918; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL671681; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL935043; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX927138; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR762476; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR933844; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR753889; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03647.1; -; Genomic_DNA.
DR   EMBL; BC014081; AAH14081.1; -; mRNA.
DR   EMBL; L21204; AAC12902.1; -; mRNA.
DR   EMBL; L21205; AAC12903.1; -; mRNA.
DR   EMBL; L21206; AAC12904.1; -; mRNA.
DR   EMBL; L21207; AAC12905.1; -; mRNA.
DR   EMBL; L21208; AAC12906.1; -; mRNA.
DR   EMBL; X57521; CAA40740.1; -; mRNA.
DR   EMBL; S70274; AAD14056.1; -; mRNA.
DR   CCDS; CCDS4758.2; -. [Q03518-1]
DR   PIR; S13427; A41538.
DR   RefSeq; NP_000584.2; NM_000593.5. [Q03518-1]
DR   RefSeq; NP_001278951.1; NM_001292022.1.
DR   PDB; 1JJ7; X-ray; 2.40 A; A=489-748.
DR   PDB; 5U1D; EM; 3.97 A; A=1-748.
DR   PDBsum; 1JJ7; -.
DR   PDBsum; 5U1D; -.
DR   AlphaFoldDB; Q03518; -.
DR   SMR; Q03518; -.
DR   BioGRID; 112753; 171.
DR   CORUM; Q03518; -.
DR   DIP; DIP-35626N; -.
DR   IntAct; Q03518; 65.
DR   MINT; Q03518; -.
DR   STRING; 9606.ENSP00000346206; -.
DR   ChEMBL; CHEMBL4523275; -.
DR   DrugBank; DB01259; Lapatinib.
DR   TCDB; 3.A.1.209.1; the atp-binding cassette (abc) superfamily.
DR   GlyGen; Q03518; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q03518; -.
DR   MetOSite; Q03518; -.
DR   PhosphoSitePlus; Q03518; -.
DR   SwissPalm; Q03518; -.
DR   BioMuta; TAP1; -.
DR   DMDM; 215273957; -.
DR   EPD; Q03518; -.
DR   jPOST; Q03518; -.
DR   MassIVE; Q03518; -.
DR   MaxQB; Q03518; -.
DR   PaxDb; Q03518; -.
DR   PeptideAtlas; Q03518; -.
DR   ProteomicsDB; 58214; -.
DR   Antibodypedia; 4017; 353 antibodies from 40 providers.
DR   CPTC; Q03518; 1 antibody.
DR   DNASU; 6890; -.
DR   Ensembl; ENST00000354258.5; ENSP00000346206.5; ENSG00000168394.13. [Q03518-1]
DR   Ensembl; ENST00000383235.4; ENSP00000372722.4; ENSG00000206297.7. [Q03518-2]
DR   Ensembl; ENST00000414467.2; ENSP00000405356.2; ENSG00000226173.4. [Q03518-2]
DR   Ensembl; ENST00000418205.2; ENSP00000401149.2; ENSG00000227816.4. [Q03518-2]
DR   Ensembl; ENST00000424897.2; ENSP00000413080.2; ENSG00000230705.4. [Q03518-2]
DR   Ensembl; ENST00000439781.2; ENSP00000415660.2; ENSG00000224212.4. [Q03518-2]
DR   Ensembl; ENST00000440894.2; ENSP00000402316.2; ENSG00000232367.5. [Q03518-2]
DR   GeneID; 6890; -.
DR   KEGG; hsa:6890; -.
DR   MANE-Select; ENST00000354258.5; ENSP00000346206.5; NM_000593.6; NP_000584.3.
DR   UCSC; uc003ocg.4; human. [Q03518-1]
DR   AGR; HGNC:43; -.
DR   CTD; 6890; -.
DR   DisGeNET; 6890; -.
DR   GeneCards; TAP1; -.
DR   HGNC; HGNC:43; TAP1.
DR   HPA; ENSG00000168394; Low tissue specificity.
DR   MalaCards; TAP1; -.
DR   MIM; 170260; gene.
DR   MIM; 604571; phenotype.
DR   neXtProt; NX_Q03518; -.
DR   OpenTargets; ENSG00000168394; -.
DR   Orphanet; 34592; Immunodeficiency by defective expression of MHC class I.
DR   PharmGKB; PA35021; -.
DR   VEuPathDB; HostDB:ENSG00000168394; -.
DR   eggNOG; KOG0058; Eukaryota.
DR   GeneTree; ENSGT00940000159023; -.
DR   HOGENOM; CLU_000604_84_3_1; -.
DR   InParanoid; Q03518; -.
DR   OMA; VINGMSV; -.
DR   OrthoDB; 5487044at2759; -.
DR   PhylomeDB; Q03518; -.
DR   TreeFam; TF105197; -.
DR   BRENDA; 7.4.2.14; 2681.
DR   BRENDA; 7.4.2.5; 2681.
DR   PathwayCommons; Q03518; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   SignaLink; Q03518; -.
DR   SIGNOR; Q03518; -.
DR   BioGRID-ORCS; 6890; 23 hits in 1165 CRISPR screens.
DR   ChiTaRS; TAP1; human.
DR   EvolutionaryTrace; Q03518; -.
DR   GeneWiki; TAP1; -.
DR   GenomeRNAi; 6890; -.
DR   Pharos; Q03518; Tbio.
DR   PRO; PR:Q03518; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q03518; protein.
DR   Bgee; ENSG00000168394; Expressed in granulocyte and 97 other tissues.
DR   ExpressionAtlas; Q03518; baseline and differential.
DR   Genevisible; Q03518; HS.
DR   GO; GO:0034451; C:centriolar satellite; IDA:HPA.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0042824; C:MHC class I peptide loading complex; IDA:UniProtKB.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0042825; C:TAP complex; IDA:UniProtKB.
DR   GO; GO:0015433; F:ABC-type peptide antigen transporter activity; IDA:UniProtKB.
DR   GO; GO:0043531; F:ADP binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0042626; F:ATPase-coupled transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042288; F:MHC class I protein binding; IEA:Ensembl.
DR   GO; GO:0023029; F:MHC class Ib protein binding; IPI:UniProtKB.
DR   GO; GO:0042605; F:peptide antigen binding; IDA:UniProtKB.
DR   GO; GO:1904680; F:peptide transmembrane transporter activity; IMP:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0046978; F:TAP1 binding; ISS:UniProtKB.
DR   GO; GO:0046979; F:TAP2 binding; IPI:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0019885; P:antigen processing and presentation of endogenous peptide antigen via MHC class I; IDA:UniProt.
DR   GO; GO:0046967; P:cytosol to endoplasmic reticulum transport; IMP:UniProtKB.
DR   GO; GO:0006952; P:defense response; IEA:Ensembl.
DR   GO; GO:0015833; P:peptide transport; IMP:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0055085; P:transmembrane transport; IBA:GO_Central.
DR   CDD; cd18589; ABC_6TM_TAP1; 1.
DR   CDD; cd03248; ABCC_TAP; 1.
DR   DisProt; DP01306; -.
DR   Gene3D; 1.20.1560.10; ABC transporter type 1, transmembrane domain; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR036640; ABC1_TM_sf.
DR   InterPro; IPR013305; ABC_Tap-like.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR039421; Type_1_exporter.
DR   PANTHER; PTHR43394:SF8; ATP BINDING CASSETTE SUBFAMILY B MEMBER 9; 1.
DR   PANTHER; PTHR43394; ATP-DEPENDENT PERMEASE MDL1, MITOCHONDRIAL; 1.
DR   Pfam; PF00664; ABC_membrane; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   PIRSF; PIRSF002773; ABC_prm/ATPase_B; 1.
DR   PRINTS; PR01896; TAP1PROTEIN.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF90123; ABC transporter transmembrane region; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS50929; ABC_TM1F; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
DR   TIGRFAMs; TIGR00958; 3a01208; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative initiation; ATP-binding;
KW   Endoplasmic reticulum; Host-virus interaction; Immunity; Magnesium;
KW   Membrane; Metal-binding; Nucleotide-binding; Peptide transport;
KW   Protein transport; Reference proteome; Translocase; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..748
FT                   /note="Antigen peptide transporter 1"
FT                   /id="PRO_0000093326"
FT   TOPO_DOM        1..15
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        16..36
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        37..53
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        54..76
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        77..92
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        93..113
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        114..133
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        134..154
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        155..186
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        187..207
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        208..227
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        228..248
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        249..298
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        299..319
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        320..328
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        329..349
FT                   /note="Helical; Name=8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        350..418
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        419..439
FT                   /note="Helical; Name=9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        440..443
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        444..464
FT                   /note="Helical; Name=10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TOPO_DOM        465..748
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          187..470
FT                   /note="ABC transmembrane type-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   DOMAIN          503..742
FT                   /note="ABC transporter"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT   REGION          375..420
FT                   /note="Part of the peptide-binding site"
FT                   /evidence="ECO:0000269|PubMed:8955196"
FT   REGION          453..487
FT                   /note="Part of the peptide-binding site"
FT                   /evidence="ECO:0000269|PubMed:8955196"
FT   BINDING         538..546
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P36370,
FT                   ECO:0000255|PROSITE-ProRule:PRU00434"
FT   BINDING         545
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000269|PubMed:11532960,
FT                   ECO:0007744|PDB:1JJ7"
FT   BINDING         641..647
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P36370"
FT   BINDING         701
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P36370"
FT   SITE            32
FT                   /note="Inter-subunit salt bridge with TAPBP"
FT                   /evidence="ECO:0000269|PubMed:26611325"
FT   VAR_SEQ         1
FT                   /note="M -> MAELLASAGSACSWDFPRAPPSFPPPAASRGGLGGTRSFRPHRGAES
FT                   PRPGRDRDGVRVPM (in isoform 2)"
FT                   /id="VSP_061432"
FT   VARIANT         7
FT                   /note="P -> S (in dbSNP:rs375389015)"
FT                   /evidence="ECO:0000269|PubMed:12878362"
FT                   /id="VAR_016801"
FT   VARIANT         17
FT                   /note="G -> R (in dbSNP:rs57640466)"
FT                   /evidence="ECO:0000269|PubMed:12878362"
FT                   /id="VAR_016802"
FT   VARIANT         110
FT                   /note="L -> V (in dbSNP:rs2228108)"
FT                   /id="VAR_048137"
FT   VARIANT         244
FT                   /note="V -> L (in dbSNP:rs36229525)"
FT                   /id="VAR_060987"
FT   VARIANT         286
FT                   /note="S -> F (in dbSNP:rs2228111)"
FT                   /id="VAR_048138"
FT   VARIANT         333
FT                   /note="I -> V (in allele TAP1*02:01, allele TAP1*03:01,
FT                   allele TAP1*04:01 and allele TAP1*x; dbSNP:rs1057141)"
FT                   /evidence="ECO:0000269|PubMed:11250043,
FT                   ECO:0000269|PubMed:12878362, ECO:0000269|PubMed:1570316,
FT                   ECO:0000269|PubMed:8248212"
FT                   /id="VAR_000092"
FT   VARIANT         370
FT                   /note="A -> V (in allele TAP1*x; dbSNP:rs2127679)"
FT                   /evidence="ECO:0000269|PubMed:11250043,
FT                   ECO:0000269|PubMed:12878362"
FT                   /id="VAR_013151"
FT   VARIANT         419
FT                   /note="G -> C (in dbSNP:rs2228110)"
FT                   /evidence="ECO:0000269|PubMed:12878362"
FT                   /id="VAR_016803"
FT   VARIANT         458
FT                   /note="V -> L (in allele TAP1*04:01; dbSNP:rs41550019)"
FT                   /evidence="ECO:0000269|PubMed:11250043,
FT                   ECO:0000269|PubMed:12878362, ECO:0000269|PubMed:8248212"
FT                   /id="VAR_013152"
FT   VARIANT         518
FT                   /note="V -> I (in allele TAP1*x; dbSNP:rs41561219)"
FT                   /evidence="ECO:0000269|PubMed:11250043"
FT                   /id="VAR_013153"
FT   VARIANT         637
FT                   /note="D -> G (in allele TAP1*02:01, allele TAP1*04:01 and
FT                   allele TAP1*x; dbSNP:rs1135216)"
FT                   /evidence="ECO:0000269|PubMed:11250043,
FT                   ECO:0000269|PubMed:12878362, ECO:0000269|PubMed:1570316,
FT                   ECO:0000269|PubMed:8168860, ECO:0000269|PubMed:8248212"
FT                   /id="VAR_000093"
FT   VARIANT         648
FT                   /note="R -> Q (in allele TAP1*04:01; dbSNP:rs1057149)"
FT                   /evidence="ECO:0000269|PubMed:11250043,
FT                   ECO:0000269|PubMed:12878362, ECO:0000269|PubMed:8168860,
FT                   ECO:0000269|PubMed:8248212"
FT                   /id="VAR_013154"
FT   VARIANT         659
FT                   /note="R -> Q (in a lung cancer cell line deficient in MHC
FT                   class I presentation; dbSNP:rs121917702)"
FT                   /evidence="ECO:0000269|PubMed:8640228"
FT                   /id="VAR_013173"
FT   VARIANT         708
FT                   /note="Q -> R (in dbSNP:rs1057149)"
FT                   /id="VAR_047514"
FT   MUTAGEN         32
FT                   /note="D->K: Complete loss of interaction with TAPBP,
FT                   resulting in impaired PLC assembly and antigen
FT                   presentation."
FT                   /evidence="ECO:0000269|PubMed:26611325"
FT   MUTAGEN         674
FT                   /note="D->A: Impairs allosteric coupling of peptide
FT                   transport to ATP hydrolysis, converting the unidirectional
FT                   active pump into a passive bidirectional nucleotide-gated
FT                   facilitator. Inactive in peptide transport when associated
FT                   with 'A-638' of TAP2."
FT                   /evidence="ECO:0000269|PubMed:25377891"
FT   STRAND          503..510
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          520..528
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          533..537
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           544..551
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          558..564
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           569..571
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           574..580
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          581..584
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          592..594
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           595..600
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           609..618
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           622..626
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           631..633
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          641..643
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           645..657
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          662..668
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   TURN            669..672
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           675..686
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           689..693
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          695..699
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           703..707
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          710..716
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   STRAND          719..724
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           726..732
FT                   /evidence="ECO:0007829|PDB:1JJ7"
FT   HELIX           735..740
FT                   /evidence="ECO:0007829|PDB:1JJ7"
SQ   SEQUENCE   748 AA;  80965 MW;  E703ECCC09417002 CRC64;
     MASSRCPAPR GCRCLPGASL AWLGTVLLLL ADWVLLRTAL PRIFSLLVPT ALPLLRVWAV
     GLSRWAVLWL GACGVLRATV GSKSENAGAQ GWLAALKPLA AALGLALPGL ALFRELISWG
     APGSADSTRL LHWGSHPTAF VVSYAAALPA AALWHKLGSL WVPGGQGGSG NPVRRLLGCL
     GSETRRLSLF LVLVVLSSLG EMAIPFFTGR LTDWILQDGS ADTFTRNLTL MSILTIASAV
     LEFVGDGIYN NTMGHVHSHL QGEVFGAVLR QETEFFQQNQ TGNIMSRVTE DTSTLSDSLS
     ENLSLFLWYL VRGLCLLGIM LWGSVSLTMV TLITLPLLFL LPKKVGKWYQ LLEVQVRESL
     AKSSQVAIEA LSAMPTVRSF ANEEGEAQKF REKLQEIKTL NQKEAVAYAV NSWTTSISGM
     LLKVGILYIG GQLVTSGAVS SGNLVTFVLY QMQFTQAVEV LLSIYPRVQK AVGSSEKIFE
     YLDRTPRCPP SGLLTPLHLE GLVQFQDVSF AYPNRPDVLV LQGLTFTLRP GEVTALVGPN
     GSGKSTVAAL LQNLYQPTGG QLLLDGKPLP QYEHRYLHRQ VAAVGQEPQV FGRSLQENIA
     YGLTQKPTME EITAAAVKSG AHSFISGLPQ GYDTEVDEAG SQLSGGQRQA VALARALIRK
     PCVLILDDAT SALDANSQLQ VEQLLYESPE RYSRSVLLIT QHLSLVEQAD HILFLEGGAI
     REGGTHQQLM EKKGCYWAMV QAPADAPE
//
